April 2019—NeoGenomics announced availability of the Ventana PD-L1 (SP142) Assay for tumor tissue from patients with the triple negative subtype of breast cancer.
Read More »NeoGenomics to acquire Genoptix
Oct. 26, 2018—NeoGenomics has entered into a definitive agreement to acquire Genoptix for $125 million in cash and 1 million shares of NeoGenomics common stock. “The acquisition of Genoptix enhances NeoGenomics’ leadership in the oncology test market, significantly expanding our coverage of oncology practices, increasing our customer reach, and leaving us better positioned for growth,” Douglas M. VanOort, NeoGenomics’ chairman ...
Read More »NeoGenomics to host molecular symposium, 1/18
January 2018—NeoGenomics will host a molecular symposium titled “NGS for Clinicians and Pathologists: An Overview of Principles and Clinical Applications,” Feb. 23–24, at Laguna Cliffs Marriott Resort and Spa, Dana Point, Calif.
Read More »Cell-free DNA tests, 2/16
February 2016—NeoGenomics has expanded its liquid biopsy testing menu to include two new tests, a NeoLab Solid Tumor Monitor and a NeoLab BTK Inhibitor Acquired Resistance test. Each of the tests uses cell-free DNA from peripheral blood plasma without the need for tissue biopsies.
Read More »NeoGenomics acquires Clarient, 12/15
December 2015—NeoGenomics has reached an agreement to acquire Clarient and its wholly owned subsidiary Clarient Diagnostic Services. Clarient, a unit of GE Healthcare’s Life Sciences business, is based in Houston and in Aliso Viejo, Calif., and has approximately 415 employees. Clarient had 2014 revenue of $127 million.
Read More »